Qiagen is working with advisers as it considers selling a minority stake in its bioinformatics unit in a deal that could value the business at more than $1B, sources tell Bloomberg’s Dinesh Nair, Michelle Davis and Tim Loh.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QGEN: